CGTX - NASDAQ

Hello and welcome everyone joining today's Cognition Therapeutics fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star one on your telephone keypad. Please note this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Mike Moyer with LifeSci Advisors. Please go ahead.

Thank you, operator, and good morning everyone. Welcome to Cognition Therapeutics' fourth quarter and year-end 2025 results conference call. With me today are Lisa Ricciardi, President and Chief Executive Officer, John Doyle, Chief Financial Officer, and Dr. Tony Caggiano, Chief Medical Officer. This morning, the company issued a press release detailing its 2025 fourth quarter and year-end results. We encourage everyone to read this morning's press release, as well as Cognition's annual report on Form 10-K, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for 30 days. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, management will be making forward-looking statements.

Actual results could differ materially from those stated or implied by those forward-looking statements due to the risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Cognition's press releases and SEC filings, including its annual report on Form 10-K and previous filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Cognition undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I would like to turn the call over to CEO Lisa Ricciardi.

Mike, thank you. Good morning, everyone. Cognition's primary focus since its inception has been on the development of zervimesine for patients with debilitating neurodegenerative diseases.

Thank you. We recently published results from our phase II SHIMMER study in DLB and showed that zervimesine has a meaningful impact across DLB symptom domains, specifically movement, cognition, function, and behavior, including psychosis. These behavioral symptoms were the subject of our recent presentation at the Alzheimer's and Parkinson's Disease Conference last week in Copenhagen. These symptoms were measured in the phase II trial using an assessment called the NPI-12, which is a 12-item index of neuropsychiatric symptoms.

This is an important finding and one of the topics that we discussed both with the FDA in our FDA type C meeting in January, as well as with our peers during the ADPD meeting. We are very encouraged by the response to this plan from our KOLs and expert consultants at ADPD. In our conversations with the FDA team, they agreed that the effects on psychosis were compelling and directed us to the Division of Psychiatry in order to define a path towards registration. The Division of Psychiatry has familiarity with trials designed to measure psychosis associated with neurologic disease. They have recently overseen registrational studies and new drug applications for Rexulti, for Alzheimer's agitation, and Nuplazid for Parkinson's disease psychosis. We look forward to meeting with the Division of Psychiatry to discuss a registrational plan for the treatment of DLB psychosis.

A meeting request with the division has already been filed. Many of you who follow this space know that psychosis is commonly associated with neurodegenerative diseases like Alzheimer's disease, frontotemporal dementia, Parkinson's disease dementia, and DLB. In DLB, psychosis is more prevalent than in other dementias and often occurs early in the course of the disease. As many as 80% of DLB patients experience psychosis. The presence of hallucinations is one of the core clinical criteria for a diagnosis of DLB. Unlike psychiatric conditions like schizophrenia, some DLB patients recognize that these images, sensations, or sounds that they are experiencing are actually hallucinations. This is understandably very stressful, both to patients and to their families, and can lead to withdrawal from social activities and isolation, negatively impacting the entire family unit. Delusions are also common in DLB.

These are often impostor delusions, where patients believe their friends and family members have been replaced by others pretending to be their family members. These delusions are difficult to manage and can accelerate the family's decision to move their loved ones into nursing care facilities. As you can see, psychosis is extremely debilitating for DLB patients. There are no approved medications for DLB patients with psychosis. Neurologists and psychiatrists have few treatment options for hallucinations and delusions, as most patients cannot tolerate traditional antipsychotics. Few clinical trials for patients with DLB psychosis have been conducted, and none have been successful to date. Most drugs in development for DLB psychosis are acute treatments as they modulate specific receptors involved in psychosis. The difference between the acute treatment and Cognition's approach is the mechanism.

Acute treatment acts rapidly to impact specific symptoms but does not change the course of the disease. Patients' disease continue to progress, their symptoms will worsen, and these acute treatments may become less effective over time.

Therefore, we believe that our decision to develop zervimesine for DLB psychosis will allow us to expedite its path to market. After completing our meeting with the Division of Psychiatry and receiving the official meeting minutes mid-year, we will issue an update in a press release.

Thank you, Tony. Before I move on, I'll add that one of the factors that led us to decide to pursue DLB psychosis was the anecdotal feedback from our expanded access program, or as we refer to it, our EAP program. We started this program in mid-2025 after we received a philanthropic donation from a patient's family. The patient had been in our phase II SHIMMER study. This family was driven to find a way to maintain access to zervimesine because of the impact they believe it had on the patient with DLB. They were focused not only on their mental health needs, but that of the broader SHIMMER trial population. Once the EAP started, it quickly filled to capacity. The level of interest from DLB patients and their physicians was and is astounding.

We still get queries from patients and families about gaining access or extending access to the drug. Now, since the EAP is open label, we're in a unique position to hear directly from patients and their loved ones, and the response has been consistent that people believe zervimesine is making a tangible difference in their daily lives. These experiences fuel our desire to complete our development work, and if approved, see this drug available all over the world. Right now, we have funding to continue the EAP program for another nine to 12 months. Now, moving on to Alzheimer's disease. As you may recall, we completed the phase II SHINE study in mild to moderate Alzheimer's disease in 2024. We saw a reduction in cognitive decline of 38%, and that is on the ADAS-Cog 11 scale in treated versus placebo patients.

This was comparable to the effects observed in phase III trials with the immunotherapeutics Kisunla and Leqembi. In SHINE, the treatment effect was most pronounced in patients with lower levels of a protein called p-tau217 in their blood. These participants experienced a 95% reduction in cognitive decline. When we met with the FDA during an end of phase II meeting in 2025, the FDA agreed with our proposal to screen for participants with lower levels of p-tau217. This strategy could expedite patient recruitment. Importantly, it will also enrich the study with patients who are most likely to benefit from zervimesine treatment.

This study met its enrollment goal at the end of 2025 with a total of 545 participants. Top line results are expected in 2027 after the last participants complete the 18-month treatment period. Given the strong results we observed with zervimesine in the mild to moderate AD trial, we remain committed to developing zervimesine for Alzheimer's disease, and we look forward to the results of our START trial. With that, John Doyle will review our financial results and provide more color around our cash position and capital requirements. John.

Thank you, Lisa. Cash, cash equivalents, and restricted cash equivalents as of December 31st, 2025, were approximately $37 million. Total grant funds remaining from the NIA were $35.7 million.

We estimate that the company has sufficient cash to fund operations and capital expenditures through the second quarter of 2027. Research and development expenses were $37.2 million for the year ended December 31st, 2025, compared to $41.7 million for 2024. The change in R&D expenses was driven by the completion of SHINE and SHIMMER clinical trials and associated professional fees. General and administrative expenses were $10.6 million for the year ended December 31st, 2025, compared to $12.3 million for 2024. This change in G&A expenses was driven primarily by reduced stock-based compensation expenses. The company reported net loss of $23.5 million, or $0.32 per basic and diluted share for the year ended December 31st, 2025.

This is compared to a net loss of $34 million or $0.86 per basic and diluted share for 2024. Lisa?

Thank you, John. I'll now turn the call back to our operator, who can open this up to questions. Nikki?

Thank you. We will move next with William Wood with B. Riley Securities. Please go ahead. Your line is open.

Hi. Thanks for taking our questions and congratulations on the very nice ending of the year. Just trying to sort of think about in terms of the DLB program, maybe you could walk us through what you see as the regulatory path forward. Should we expect your next trial, I believe you said in the past it might be a phase IIb. Would that be expected to be registrational, or do you think you could go to phase III directly? What are your current thinking on your DLB trial, both in terms of size and duration but also primary endpoint? I have a follow-up.

Yeah. Yeah, thank you for the question. As we mentioned, our intent is to develop this now for a label relating to psychosis in DLB, like we saw, as just mentioned, with Nuplazid and Rexulti in Alzheimer's disease and Parkinson's disease dementia. Now, you know, we have not completed, you know, the FDA meetings yet to comment on exactly what the outcome measure will be. We have to work on that, but you can imagine it'll be very similar to what we've done here before. Certainly our intent is to move as expeditiously as possible through registrational trials. Again, until we have the meeting with FDA and have minutes, it'd be premature to comment exactly what that would look like.

Okay, got it. In terms of you also had reported that you had numerous other additional trials, including pharmacology in healthy volunteers, DDI, bioavailability food. I believe also you were switching from a capsule to a tablet formation. Is there any update on any of these additional trials that could aid in your moving forward quickly into your DLB psychosis? Additionally, what other remaining gating steps do you sort of see in getting that DLB psychosis trial underway once you have the regulatory feedback?

Yeah, you're correct. Those are the studies that we'd want to complete before starting those trials. Again, you know, based on the nature of these studies, these are very low-risk studies, right? They're really informing us on things such as do we need to add any instructions as to whether people should take drug with or without food or have no instructions whatsoever. These are extremely low risk that we just need to get behind us. As you mentioned, you're correct, we're moving from a capsule form to a tablet form, which we think will be better as this is eventually, right, hopefully, once approved, commercialized. Those are all moving along and we look to accomplish this, you know, this all in this year, 2026.

Okay. Got it. Helpful. Thank you very much. I'll hop back in the queue.

Thank you. We will move next with Daniil Gataulin with Chardan. Please go ahead. Your line is open.

Hey. Good morning, guys. Thank you for taking my question. First, how does the effect of zervimesine on behavioral domains in DLB affect your thinking about pursuing also behavioral domains in Alzheimer's disease? Or is the current focus still on an overall slowing of the disease progression?

Thanks for the question, Daniil. We want to see the results of our START trial. Big trial, important trial. We hope it builds on the SHINE results, which we've already seen, particularly those impressive effects in patients with low p-tau. With that kind of data, we can then prioritize in the out years, what do we do next? Right now on the fairway is the DLB study as a first priority. While that study is recruiting and getting underway, we anticipate seeing the results of START, which is the early AD trial. We by no means given up on AD. It's a question of prioritization. As a small company, we've chosen DLB psychosis, and we'll get feedback. Such great information sometime next year from START in AD.

Got it. Okay. Makes sense. For DLB, you will be having the meeting with the FDA. What about alignment on psychosis with the EMA? Where are you in those meetings, and do you anticipate the trial to be including sites both in the United States and Europe to support global approval?

Yeah, thank you. We haven't really announced exactly where the trial will be. Certainly, once we have agreement with FDA, you know, as we've done with AD, we'll want to seek alignment with EMA before launching trials there. It's a little premature to talk about exactly what those plans are.

Got it. All right. Thank you. Thank you for taking my questions.

We have a bit, right? Most of our studies are done on standard of care background medications. Obviously in Alzheimer's disease and our mild to moderate study, this was acetylcholinesterase inhibitors and memantine. Interestingly now, most people with DLB are also on acetylcholinesterase inhibitors. In our trial, and this is all published information, about 80 or 85% of individuals were on acetylcholinesterase inhibitors. The effects of our drug have been on top of these standard of care. Similarly, in our START trial in early AD, we've allowed people to be on and have been on, provided they are on a stable maintenance course of the immunotherapies, right? Lecanemab and donanemab.

Thank you. We will move next with Sumant Kulkarni with Canaccord. Please go ahead. Your line is open.

Good morning. Thanks for taking my questions. I have a couple. First, what's the state of the art in terms of the hypothesis behind zervimesine's mechanism of action on psychosis? And do you have any similar anecdotes from patients in your SHINE study?

Sumant, what was the second part of your second question?

The second part was if, just like you had some anecdotes that led you to explore psychosis in DLB, did you have any similar anecdotes on the Alzheimer's study?

Got it. Tony, you wanna take the first question?

Sure, yeah. You know, we mentioned briefly, but obviously we didn't get into too much detail in our discussion. You're right. We don't believe that we are impacting the receptors particularly, you know, known to be responsible for psychosis. What we believe, much like the global state of the disease, is that we're interrupting the basic pathophysiology by just like in Alzheimer's disease, blocking the ability of Aβ oligomers to interact with neurons. We have similar data showing that we prevent the interaction of alpha-synuclein from interacting with their receptors, thereby preventing, right, the basic damage to neurons. Now, the symptomatology in DLB from alpha-synuclein toxicity is based on where that toxicity is occurring.

Again, we believe that we are able to impact the broad symptomatology of the disease and that those effects, as we noted, were most notable or most measurable within the psychosis. That's what we're pursuing.

Got it. My follow-up. In your DLB, I guess in your proposed DLB psychosis trial, what would the time point be to the primary endpoint on psychosis? And do you expect to have secondary endpoints involving cognition? I'm asking because, with reference to your potential to eventually attain a disease-modifying label.

We have not announced exactly what the study looks like and the duration and so forth. That'll certainly be a topic of our discussion with FDA. You know, obviously you've seen the results of our SHIMMER trial, and we won't want to stray too much from that design. Absolutely we will have other measures, secondary measures which you know are ranked and protected, looking at you know cognition and motor function and sleep and so forth. Again, because as you saw with the results of the SHIMMER trial, you know, we are very impressed by the global impact of the drug on the disease. Certainly eventually we'll want to study those other impacts as well.

The reason we're focusing right now on psychosis is because the impact of the drug on psychosis is really quite strong, and that gives us the ability to do smaller, faster trials and hopefully a much more efficient path to market.

Got it. Thank you.

Thank you. At this time, there are no further questions in queue. I will now turn the meeting back to CEO Lisa Ricciardi for closing comments.

All right, Nikki. We are looking forward to meeting with the FDA's Division of Psychiatry shortly. As Tony said, we can finalize our plans and timing for studying DLB psychosis. This is an important indication. It's currently unaddressed by any approved or unapproved medications. Based on our phase II findings and anecdotal feedback, as we discussed in participants in our EAP program, we believe zervimesine has the potential to be a first-in-class treatment option for DLB patients with psychosis. With that, thank you all for joining us today.